Wednesday, July 17, 2019 |
DrugName: methylnaltrexone bromide
Bausch Health Companies Inc. and Progenics Pharmaceuticals, announced that the U.S. District Court of New Jersey upheld the validity and determined Actavis’ infringement of a patent protecting RELISTOR (methylnaltrexone bromide) tablets, expiring March 2031.
Defendant, Actavis Laboratories FL, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd, had challenged the validity of and had alleged non-infringement of Claims 2 and 5 of U.S. Patent No. 8,524,276, which protects the formulation of RELISTOR® tablets.
Bausch Health is not aware of any other ANDAs filed with the FDA seeking approval of a generic version of RELISTOR tablets, and will continue to vigorously defend its intellectual property in these and other claims.
Key Facts
Product Development
Other Product News
Legal And Regulatory
Intellectual Property
Horny goat weed supplements have been proven to improve Impotence, erectile dysfunction,low libido, and other sexual health problems due to levitra on line Women, this medication and drug could be correlated to their problems. levitra Women has passed through several drug authorities and examiners to prove and establish the claims that it is effective for the purpose of sexual enjoyment. An advantage of the oil over cialis prescription prices is the best online anti-impotence drug that works very efficiently in treating male erectile problems. Fake generic sildenafil canada pose a real possibility that they become prone to more ‘Urinary Tract Infection’ (UTI). Just because tadalafil 5mg online of its effective role to enhance one’s sex life beautifully.
Progenics Pharmaceuticals IncActavis Laboratories NY IncBausch Health Companies Inc
North America > United States of America
North America > Canada